Summary
• Bluejay Diagnostics (BJDX) sees a 6.5% drop in after-hours trading, priced at $0.6805.
• The company announced completion of commercial-scale antibody production targeting IL-6, but investor sentiment remains cautious.
• BJDX has a “Hold” rating from analysts amidst significant volatility and a year-to-date decline of 86.1%.
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) is experiencing a sharp decline of 6.5% in after-hours trading, as the stock is priced at $0.6805 compared to its last close of $0.728. The after-hours session has seen limited trading volume at 4,810 shares, despite a significant recent announcement from the company.
Commercial-Scale Antibody Production Completed
The notable news driving attention to Bluejay Diagnostics comes from its announcement on December 29, 2025, regarding the completion of commercial-scale production of both polyclonal and monoclonal antibodies that target interleukin-6 (IL-6). This biomarker is indicated for use in inflammatory and critical-care applications, which positions the company for potential growth within the healthcare sector.
However, despite this announcement, investor sentiment appears to be cautious, as reflected in the stock’s decline following the news.
Market and Technical Picture
The stock shows bearish trends, with a 52-week low of 4.46 and a significant yearly decline of 86.1% year-to-date. The recent performance data reveals a high volatility environment, with weekly and monthly changes at -15.1% and -50.8%, respectively. The relative strength index (RSI) stands at 19.21, indicating that the stock is in oversold territory.
With average trading volume over the past 10 days at approximately 150,932 shares, compared to an average of 2,562,053 shares over the last three months, the current volume suggests reduced trading interest in the name. Moving averages reveal steep discounts; the stock’s 20-day, 50-day, and 200-day simple moving averages stand at -31.2%, -54.3%, and -63.8%, respectively.
Analyst Sentiment and Ratings
Currently, Bluejay Diagnostics holds a “Hold” rating from analysts, reflecting a cautious stance following the latest developments. The company’s earnings have recently shown significant surprises, with a current actual earnings change of -112.4% from estimates, highlighting volatility in financial performance.
Closing Remarks
With the stock reacting negatively despite the recent announcement of antibody production, concern over the company’s fundamentals appears to dominate trading sentiment. Investors will likely continue to assess how this latest development impacts Bluejay’s operational trajectory in the coming sessions.